Publications by authors named "Duojie Zhang"
Article Synopsis
- The study evaluated the effectiveness and safety of first-line treatments for metastatic castration-resistant prostate cancer (mCRPC) through a systematic analysis of trials published until April 2023.
- A network meta-analysis of seven randomized controlled trials involving 6,641 patients showed that docetaxel+prednisone (DP) and cabazitaxel+prednisone (CP) significantly improved overall survival compared to abiraterone and placebo.
- The analysis recommended cabazitaxel 20 mg/m+prednisone (C20P) as the best first-line treatment, followed by DP, with enzalutamide and abiraterone as later options, and radium-223 for patients with bone metastases.
